News
Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...
GlobalData on MSN1d
Merck KGaA nears $3.5bn deal for SpringWorksMerck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...
With that, let's consider two dividend-paying companies that look like strong buys for the next two decades: Medtronic ( MDT -0.19%) and Merck ( MRK 3.72%).
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...
With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback